Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05640531 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771
A Phase 1 study of Bioavailability, sponsored by Wockhardt.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05640531: Completed Phase 1 study of Bioavailability, sponsored by Wockhardt.
NCT05640531 is a Phase 1 study of Bioavailability that has completed, run by Wockhardt. The registered enrollment target is 36 participants, roughly in line with the 34-participant average among 8 other Bioavailability trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05640531, a Phase 1 study of Bioavailability, has completed, sponsored by Wockhardt.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study is planned to assess the safety and pharmacokinetic profile in normal healthy subjects in US for WCK 771 with doses ranging from 600 mg to 1000 mg BID for 5 days. In the proposed Phase I MAD study, a subject will be administered 600mg, 800mg, and 1000mg WCK 771 BID for 5 days (Ten doses) or an identical placebo as intravenous infusion.
Primary Outcome
By monitoring the adverse events reported
Conditions Studied
Interventions
- DRUG WCK 771 IV Infusion
- OTHER Placebo IV Infusion
Study Locations (1)
Texas
- PPD Phase I Clinic, 7551 Metro Center Drive, Suite 200 - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-12-01 |
| Est. Completion | 2012-06-27 |
| Phase | Phase 1 |
What the finished NCT05640531 record still lists
NCT05640531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, roughly in line with the 34-participant average among 8 other Bioavailability trials with a reported enrollment target.
The record links to 1 condition, with Bioavailability appearing as the primary indexed condition, and to 2 interventions - of which WCK 771 IV Infusion is the first listed.
NCT05640531 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05640531 about?
NCT05640531 is a clinical study titled "Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771". The present study is planned to assess the safety and pharmacokinetic profile in normal healthy subjects in US for WCK 771 with doses ranging from 600 mg to 1000 mg BID for 5 days. In the proposed Phase I MAD study, a subject will be administered 600mg, 800mg, and 1000mg WCK 771 BID for 5 days (Ten ...
What is the current status of trial NCT05640531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-12-01. Estimated completion is 2012-06-27.
What conditions does trial NCT05640531 study?
This clinical trial studies the following conditions: Bioavailability.
What interventions are being tested in trial NCT05640531?
The interventions under investigation include: WCK 771 IV Infusion (DRUG), Placebo IV Infusion (OTHER).
Who is sponsoring clinical trial NCT05640531?
This trial is sponsored by Wockhardt, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05640531 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bioavailability
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05640531's enrollment target sits among peer trials
36 5th of 8 higher than 4 of 8 other Bioavailability trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bioavailability trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Curcumin and Retinal Study
RECRUITING · Phase 1
-
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
COMPLETED · Phase 1
-
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
COMPLETED · Phase 1
-
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
COMPLETED · Phase 1
-
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
COMPLETED · Phase 1
-
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI